Thrombin activatable fibrinolysis inhibitor (TAFI) is not associated with recurrent miscarriage.

Abstract

AIM(S) The present study aimed to discover whether there is an association between thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels and recurrent miscarriage (RM). In particular, TAFI antigen levels of women with RM were compared with those of a control group of women with previous uncomplicated pregnancies. METHOD(S) Group 1 comprised 48 women with RM, defined as the occurrence of two or more fetal losses before 20 weeks of gestation. Group 2 (the control group) was made up of 40 women who had undergone at least two healthy pregnancies and had no history of miscarriage. Group 1 was then stratified in to two groups according to the number of pregnancy losses and group 1A (2 pregnancy losses) consisted of 22 women whereas group 1B (three or more pregnancy losses) consisted of 26 women. RESULTS No difference was observed with regard to serum TAFI antigen levels between groups 1 and 2. There was also no statistical difference in serum TAFI antigen levels between group 1A and group 1B. CONCLUSION The findings of the current study indicated that TAFI antigen levels are not associated with RM. Further multi-centric research with more subjects is needed to better evaluate the role of TAFI in RM.

Cite this paper

@article{Sezer2011ThrombinAF, title={Thrombin activatable fibrinolysis inhibitor (TAFI) is not associated with recurrent miscarriage.}, author={Selda Demircan Sezer and A Baz and Mustafa K{\"{u}ç{\"{u}k and Ali Rıza Odabaşi and Mukadder Serter and Hasan Y{\"{u}ksel}, journal={Clinical and experimental obstetrics & gynecology}, year={2011}, volume={38 3}, pages={228-31} }